BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26152012)

  • 1. The impact of LH, E2, and P level of HCG administration day on outcomes of in vitro fertilization in controlled ovarian hyperstimulation.
    Wei M; Zhang XM; Gu FL; Lv F; Ji YR; Liu KF; She H; Hu R
    Clin Exp Obstet Gynecol; 2015; 42(3):361-6. PubMed ID: 26152012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone/estradiol ratio <0.25 on the day of human chorionic gonadotropin administration is associated with adverse pregnancy outcomes in prolonged protocols for in vitro fertilization/intracytoplasmic sperm injection.
    Li Y; Luo K; Tang Y; Lin G; Lu G; Gong F
    Taiwan J Obstet Gynecol; 2017 Feb; 56(1):27-31. PubMed ID: 28254221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles.
    Wu Z; Li R; Ma Y; Deng B; Zhang X; Meng Y; Chen X; Liu P; Qiao J
    Reprod Biomed Online; 2012 May; 24(5):511-20. PubMed ID: 22417667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
    Cicek MN; Kahyaoglu I; Kahyaoglu S
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
    Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
    JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.
    Ye H; Huang GN; Zeng PH; Pei L
    J Assist Reprod Genet; 2009 Mar; 26(2-3):105-11. PubMed ID: 19225876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of progesterone/estradiol ratio on day of hCG administration and pregnancy outcomes in high responders undergoing in vitro fertilization.
    Lee FK; Lai TH; Lin TK; Horng SG; Chen SC
    Fertil Steril; 2009 Oct; 92(4):1284-1289. PubMed ID: 18829018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
    Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
    Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility and clinical significance of pre-ovulatory serum progesterone level and progesterone/estradiol ratio on the day of human chorionic gonadotropin administration in infertile women undergoing repeated in vitro fertilization cycles.
    Lin YJ; Lan KC; Huang FJ; Lin PY; Chiang HJ; Kung FT
    Reprod Biol Endocrinol; 2015 May; 13():41. PubMed ID: 25967104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
    Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles.
    Papaleo E; Corti L; Vanni VS; Pagliardini L; Ottolina J; De Michele F; La Marca A; Viganò P; Candiani M
    Arch Gynecol Obstet; 2014 Jul; 290(1):169-76. PubMed ID: 24549270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of low-dose hCG to rFSH during ovarian stimulation for IVF/ICSI: is it beneficial?
    Partsinevelos GA; Antonakopoulos N; Kallianidis K; Drakakis P; Anagnostou E; Bletsa R; Loutradis D
    Clin Exp Obstet Gynecol; 2016; 43(6):818-825. PubMed ID: 29944230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.